12,383 results match your criteria Lymphoma Follicular

Primary follicular lymphoma of the duodenum: a case report and review of literatures.

Gastroenterol Hepatol Bed Bench 2021 ;14(2):185-189

Division of Gastroenterology, Department of Internal Medicine, Hatyai Hospital, Songkhla, Thailand.

Follicular lymphoma (FL) is one of the most common types of non-Hodgkin lymphoma (NHL). The gastrointestinal tract is the most involved extra-nodal site of NHL. Primary duodenal FL (DFL) is a rare entity with only a few reported cases. Read More

View Article and Full-Text PDF
January 2021

Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma.

Hum Pathol 2021 May 5. Epub 2021 May 5.

Department of Pathology, University of Michigan, Ann Arbor, MI, USA. Electronic address:

MYC rearrangement is a relatively rare genetic abnormality in follicular lymphoma (FL). In this study, we evaluated the relative frequency of MYC rearrangement in 522 cases of FL and studied their clinicopathologic, cytogenetic and molecular characteristics. FISH studies for MYC (break-apart probe), MYC/IGH, IGH/BCL2, and BCL6 rearrangements were performed on tissue microarrays. Read More

View Article and Full-Text PDF

B Cell Lymphomas of the GI Tract.

Curr Gastroenterol Rep 2021 May 8;23(7). Epub 2021 May 8.

Division of Hematology/Oncology, Northwestern University, Chicago, IL, USA.

Purpose Of The Review: Primary GI lymphomas of B cell origin are a diverse group of lymphomas. In this article, we provide an overview of the diagnosis, pathologic and molecular features, and management of these varied lymphomas.

Recent Findings: The most common primary GI lymphomas are diffuse large B cell lymphoma (DLBCL) and marginal zone lymphomas (MZL), but follicular lymphomas (FL), mantle cell lymphomas (MCL), post-transplant lymphoproliferative disorders (PTLD), and Burkitt lymphoma of the GI tract also occur. Read More

View Article and Full-Text PDF

Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.

PLoS One 2021 4;16(5):e0248886. Epub 2021 May 4.

Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Galicia, Spain.

B-cell lymphoproliferative disorders exhibit a diverse spectrum of diagnostic entities with heterogeneous behaviour. Multiple efforts have focused on the determination of the genomic drivers of B-cell lymphoma subtypes. In the meantime, the aggregation of diverse tumors in pan-cancer genomic studies has become a useful tool to detect new driver genes, while enabling the comparison of mutational patterns across tumors. Read More

View Article and Full-Text PDF

A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor.

Int J Surg Pathol 2021 May 3:10668969211013402. Epub 2021 May 3.

71069The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Histiocytic/dendritic cell tumors are rare in clinical practice. It is postulated that they originate from bone marrow stem cells. Accumulating evidence has established the existence of immunoglobulin gene and T-cell receptor gene rearrangements in these tumors. Read More

View Article and Full-Text PDF

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.

Curr Oncol Rep 2021 May 3;23(7):76. Epub 2021 May 3.

University of Southampton, Southampton, UK.

Purpose Of Review: Epigenetic modifier gene mutations are common in patients with follicular lymphoma. Here we review the pathogenesis of these mutations and how they are targeted by epigenetic drugs including EZH2 inhibitors in both mutated and wild-type disease.

Recent Findings: The use of EZH2 inhibitor tazematostat in early phase clinical trials has proved encouraging in the treatment of follicular lymphoma harbouring an EZH2 mutation; however, responses are also seen in patients with wild-type disease which is partially explained by the off target effects of EZH2 inhibition on immune cells within the tumour microenvironment. Read More

View Article and Full-Text PDF

Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.

Hematol Oncol 2021 May 2. Epub 2021 May 2.

Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Bendamusutine plus rituximab (BR) regimen is one of the standard regimens for indolent B-cell lymphomas, yet the possibility of reduction of cycles of BR therapy without compromising therapeutic effects is not still uncovered. We retrospectively surveyed 57 cases including 40 follicular lymphoma cases who underwent BR regimen in our institute. The overall response (OR) rate and complete response (CR) rate were 86. Read More

View Article and Full-Text PDF

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.

Cancer Sci 2021 May 1. Epub 2021 May 1.

Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China.

The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in patients with refractory B-cell lymphoma. In our study, 3 patients with refractory mantle cell lymphoma (MCL) and 4 patients with refractory follicular lymphoma (FL) reached stable disease (SD), partial remission (PR), or progression of disease (PD) after first-time humanized anti-CD19-CAR T-cell therapy. They received ibrutinib as a salvage treatment and kept an SD in the following 7-16 mo, but their disease progressed again during ibrutinib salvage treatment. Read More

View Article and Full-Text PDF

Immune infiltrate diversity confers a good prognosis in follicular lymphoma.

Cancer Immunol Immunother 2021 Apr 30. Epub 2021 Apr 30.

Division of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

Background: Follicular lymphoma (FL) prognosis is influenced by the composition of the tumour microenvironment. We tested an automated approach to quantitatively assess the phenotypic and spatial immune infiltrate diversity as a prognostic biomarker for FL patients.

Methods: Diagnostic biopsies were collected from 127 FL patients initially treated with rituximab-based therapy (52%), radiotherapy (28%), or active surveillance (20%). Read More

View Article and Full-Text PDF

Expression Level of ADAMTS1 in Granulosa Cells of PCOS Patients Is Related to Granulosa Cell Function, Oocyte Quality, and Embryo Development.

Front Cell Dev Biol 2021 12;9:647522. Epub 2021 Apr 12.

Center for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1) is an extracellular matrix metalloproteinase that plays an important role in the process of ovulation. According to previous studies, the expression level of ADAMTS1 in the granulosa cells of polycystic ovarian syndrome (PCOS) patients and the mechanism for regulating oocyte quality and embryonic development potential are still unclear. Our research clarified that ADAMTS1 was significantly increased in granulosa cells of PCOS patients as compared to ovulatory controls. Read More

View Article and Full-Text PDF

Effect of Extract on Dermal Papilla Cell Proliferation and Hair Growth.

Ann Dermatol 2020 Oct 29;32(5):395-401. Epub 2020 Sep 29.

Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.

Background: (CZ) belongs to the genus Chrysanthemum, also known as 'Gu-Jeol-Cho' in Korea. CZ has been used as herbal remedy to manage cough, hypertensive disorders, pharyngitis, bronchitis, gastroenteritis, pneumonia, bladder diseases and common cold. However, its effect on hair growth has not been documented. Read More

View Article and Full-Text PDF
October 2020

Occupational exposure to glyphosate and risk of lymphoma:results of an Italian multicenter case-control study.

Environ Health 2021 Apr 28;20(1):49. Epub 2021 Apr 28.

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Background: The International Agency for Research on Cancer (IARC) recently classified glyphosate, the most used herbicide worldwide, as a probable human carcinogen. We inquired into the association between occupational exposure to glyphosate and risk of lymphoma subtypes in a multicenter case-control study conducted in Italy.

Methods: The Italian Gene-Environment Interactions in Lymphoma Etiology (ItGxE) study took place in 2011-17 in six Italian centres. Read More

View Article and Full-Text PDF

Management of Angioimmunoblastic T-Cell Lymphoma (AITL) and other T Follicular Helper Cell lymphomas (TFH PTCL).

Semin Hematol 2021 Apr 19;58(2):95-102. Epub 2021 Mar 19.

Division of Hematology/Oncology, University of Virginia, Charlottesville, VA. Electronic address:

Despite the remarkable improvements in the treatment and outcome of patients with aggressive B-cell lymphoma, the peripheral T-cell lymphomas (PTCL) continue to carry a poor prognosis with the presently available treatment options. The PTCL are very rare diseases that account for only 10,000 to 15,000 new cases per year in the United States. The World Health Organization's 2016 classification describes 29 distinct subtypes of PTCL, thus making these both rate and incredibly heterogenous. Read More

View Article and Full-Text PDF

Clinicopathological factors and tumor microenvironment markers predicting watch-and-wait discontinuation in 82 patients with follicular lymphoma.

Eur J Haematol 2021 Apr 27. Epub 2021 Apr 27.

Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.

Objectives: In this study, we aimed to determine the clinicopathological factors influencing the treatment-free period in patients with follicular lymphoma (FL) using a watch-and-wait (WW) strategy.

Methods: We retrospectively assessed histopathological parameters of 82 patients with FL.

Results: The median time from diagnosis to WW discontinuation was 62 months (range, 3-138), and median follow-up was 86 months (range, 3-183). Read More

View Article and Full-Text PDF

Treating lymphoma is now a bit EZ-er.

Blood Adv 2021 Apr;5(8):2256-2263

Jewish General Hospital, McGill University, Montreal, QC, Canada.

Tazemetostat represents the first epigenetic therapy approved for the treatment of follicular lymphoma (FL). It inhibits the activity of the enhancer of zeste homolog 2 (EZH2) histone methyltransferase, the first of a multitude of epigenetic regulators that have been identified as recurrently mutated in FL and germinal center diffuse large B-cell lymphoma. In this review, we discuss the initial discovery and ongoing exploration of the functional role of EZH2 mutations in lymphomagenesis. Read More

View Article and Full-Text PDF

EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma.

Hemasphere 2021 May 21;5(5):e559. Epub 2021 Apr 21.

Department of Medicine III, LMU Hospital, Munich, Germany.

View Article and Full-Text PDF

Bilateral Chylothorax and Chylous Ascites: A Rare Presentation of an Uncommon Disorder.

Cureus 2021 Mar 22;13(3):e14044. Epub 2021 Mar 22.

Nephrology, University of California Los Angeles, Los Angeles, USA.

We describe the case of a 62-year-old female who presented with gradually progressing abdominal distension and dyspnea. Computed tomography (CT) chest and abdomen revealed large bilateral pleural effusions with large ascites, a mid-abdominal mass, and peritoneal carcinomatosis. Pleural and peritoneal tap revealed chylous fluid, and the biopsy findings from abdominal mass were consistent with follicular lymphoma. Read More

View Article and Full-Text PDF

Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas.

Blood Rev 2021 Apr 20:100832. Epub 2021 Apr 20.

Mater Research Institute, University of Queensland, Brisbane, QLD, Australia; Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia. Electronic address:

Over the past decade therapies targeting the PD-1 axis with monoclonal antibodies to reinstate host immune function have revolutionized the clinical management of some cancers but have had minimal impact on others. This dichotomy is exemplified by B cell lymphomas. Whilst striking results are observed in classical Hodgkin Lymphoma (cHL) and Primary Mediastinal B Cell Lymphoma (PMBL), responses in other B cell lymphomas are infrequent. Read More

View Article and Full-Text PDF

Update on the role of copanlisib in hematologic malignancies.

Ther Adv Hematol 2021 9;12:20406207211006027. Epub 2021 Apr 9.

Division of Hematology/Oncology, Georgia Cancer Center at Augusta University, 1120 15th St, CN-5333, Augusta, GA 30912, USA.

Clinical research in hematologic malignancies is continually advancing with emerging concepts in therapy and evolving results from clinical protocols. Targeting of the PI3K pathway remains a valuable treatment across both hematologic and solid malignancies. There are currently four United States Food and Drug Administration (FDA)-approved PI3K inhibitors, with several others in development. Read More

View Article and Full-Text PDF

Radiological and pathological correlation of a rare case of primary breast follicular lymphoma in a male patient, presenting as gynaecomastia.

J Med Imaging Radiat Oncol 2021 Apr 21. Epub 2021 Apr 21.

Department of Medical Imaging, Royal Perth Hospital, Perth, Western Australia, Australia.

We present an exceptionally rare case of primary breast follicular lymphoma in a male patient, who presented to us with gynaecomastia for investigation. To our knowledge there have only been two other cases published in the literature to date. In Western Australia, there have been no cases in at least the past 10 years. Read More

View Article and Full-Text PDF

Extracellular vesicles shed by follicular lymphoma B cells promote the polarization of bone marrow stromal cell niche.

Blood 2021 Feb 24. Epub 2021 Feb 24.

Faculté de Médecine, Rennes, France.

Follicular Lymphoma (FL) originates in the lymph nodes (LN) and infiltrates bone marrow (BM) early in the course of the disease. BM FL B cells are characterized by a lower cytological grade, a decreased proliferation, and a specific phenotypic and subclonal profile. Mesenchymal stromal cells (MSC) obtained from FL BM display a specific gene expression profile (GEP), including enrichment for a lymphoid-stromal cell signature, and an increased capacity to sustain FL B-cell growth. Read More

View Article and Full-Text PDF
February 2021

Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future.

Hemasphere 2021 Feb 28;5(2):e524. Epub 2021 Jan 28.

Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands.

Since 2018, 2 chimeric antigen receptor (CAR) T-cell therapies received approval from the European Medicine Agency, with list prices around 320 000 Euro (€) (EUR) per treatment. These high prices raise concerns for patient access and the sustainability of healthcare systems. We aimed to estimate the costs and budget impact associated with CAR T-cell therapies for current and future indications in hematological cancers from 2019 to 2029. Read More

View Article and Full-Text PDF
February 2021

Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.

Blood Adv 2021 Apr;5(8):2063-2074

UMR 1236, Univ Rennes, INSERM, Etablissement Français du Sang Bretagne, Rennes, France.

The immunomodulatory drug lenalidomide is used in patients with follicular lymphoma (FL) with the aim of stimulating T-cell antitumor immune response. However, little is known about the effects of lenalidomide on T-cell biology in vivo in patients with FL. We thus undertook an extensive longitudinal immunologic study, including phenotypic, transcriptomic, and functional analyses, on 44 first-line and 27 relapsed/refractory patients enrolled in the GALEN trial (Obinutuzumab Combined With Lenalidomide for Relapsed or Refractory Follicular B-Cell Lymphoma) to test the efficacy of lenalidomide and obinutuzumab combination in patients with FL. Read More

View Article and Full-Text PDF

Follicular tissue fragments in fine-needle aspiration cytology of lymph nodes: A useful clue in differential diagnosis of follicular lymphoma and reactive follicular hyperplasia.

Diagn Cytopathol 2021 Apr 20. Epub 2021 Apr 20.

Department of Pathology, Showa University School of Medicine, Tokyo, Japan.

Background: In Fine-needle aspiration cytology (FNAC) of lymph nodes, tissue fragments derived from follicular structures may be observed in specimens. We defined such tissue fragments as follicular tissue fragments (FTF), and investigated differences in cytological findings for FTFs of each histological type.

Method: A total of 41 cases with FNAC of lymph nodes were examined. Read More

View Article and Full-Text PDF

Altered Spectrum of Lymphoid Neoplasms in a Single-Center Cohort of Common Variable Immunodeficiency with Immune Dysregulation.

J Clin Immunol 2021 Apr 19. Epub 2021 Apr 19.

University of Freiburg, Freiburg, Germany.

Purpose: Common variable immune deficiency (CVID) confers an increased risk of lymphoid neoplasms, but reports describing the precise WHO specification of the lymphoma subtypes and their immunological environment are lacking. We therefore classified lymphomas-occurring in a cohort of 21 adult CVID patients during a 17-year period at our center-according to the 2016 WHO classification and characterized the local and systemic immunological context RESULTS: The median time between the onset of CVID and lymphoma was 14 years. Patients showed a high prevalence of preceding immune dysregulation: lymphadenopathy (n = 13, 62%), splenomegaly (n = 18, 86%), autoimmune cytopenia (n = 14, 67%), and gastrointestinal involvement (n = 15, 71%). Read More

View Article and Full-Text PDF

Spinal anesthesia in a patient on monoclonal antibody treatment: a poisoned chalice? A case report.

Reg Anesth Pain Med 2021 Apr 19. Epub 2021 Apr 19.

Anesthesiology, Imeldaziekenhuis, Bonheiden, Belgium

Background: Paraplegia is a rare complication of spinal anesthesia.

Case Presentation: We report a case of a 68-year-old man who developed postoperative paraplegia and hypoesthesia after spinal anesthesia for an otherwise uncomplicated transurethral resection of the prostate. Acute transverse myelitis was diagnosed based on urgent MRI. Read More

View Article and Full-Text PDF

Mechanistic understanding of the combined immunodeficiency in complete human CARD11 deficiency.

J Allergy Clin Immunol 2021 Apr 16. Epub 2021 Apr 16.

Department of Pediatrics, British Columbia Children's Hospital, The University of British Columbia, Vancouver, BC, Canada; Experimental Medicine Program, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada. Electronic address:

Background: Germline pathogenic variants impairing the caspase recruitment domain family member 11 (CARD11)-B cell CLL/lymphoma 10 (BCL10)-MALT1 paracaspase (MALT1) [CBM] complex are associated with diverse human diseases including combined immunodeficiency (CID), atopy, and lymphoproliferation. However, the impact of CARD11 deficiency on human B cell development, signalling, and function is incompletely understood.

Objective: We sought to determine the cellular, immunological, and biochemical basis of disease for two unrelated patients who presented with profound CID associated with viral and fungal respiratory infections, interstitial lung disease, and severe colitis. Read More

View Article and Full-Text PDF

Flow Cytometry in the Diagnosis of Canine B-Cell Lymphoma.

Front Vet Sci 2021 19;8:600986. Epub 2021 Mar 19.

Dipartimento di Medicina Veterinaria, Università degli Studi di Milano, Lodi, Italy.

B cell lymphoma (BCL) is a heterogeneous group of lymphoid malignancies which comprise the majority of canine lymphomas. Diffuse large B cell lymphoma is the most common lymphoma subtype in dogs but other subtypes (e.g. Read More

View Article and Full-Text PDF

Malignant Lymphoma Mimicking Retroperitoneal Fibrosis.

Intern Med 2021 Apr 19. Epub 2021 Apr 19.

Department of Internal Medicine, Keiaido Hospital, Japan.

View Article and Full-Text PDF

Concurrent TP53 Mutation and Deletion in Refractory Low-grade Follicular Lymphoma.

Clin Lymphoma Myeloma Leuk 2021 Mar 18. Epub 2021 Mar 18.

Department of Hematopathology, MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article and Full-Text PDF